Brain+ to present at DTx East 2023, a global summit for the digital therapeutics’ community, held in Boston, US on 26-28 September
Copenhagen, Denmark, September 13, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)
- Brain+ founder and CEO, Kim Baden-Kristensen has been invited to give a keynote presentation at the conference on the topic of “Truly Defining Digital Therapeutics”
- The DTx conference series is the main meeting point for all key stakeholders in the global digital therapeutics’ community
Brain+ informs that the company’s co-founder and CEO, Kim Baden-Kristensen has been invited to deliver a keynote at the DTx East 2023 summit, part of the 18th Annual Digital Therapeutics (DTx) Conference Series, which will be held in Boston Massachusetts, US on 26 – 28 September, 2023. The keynote is scheduled for 26 September at 11:40 a.m. EST and will present Brain+’ DTx products for dementia under the topic of ’Truly Defining Digital Therapeutics’.
Digital therapeutics (DTx) is a rapidly evolving industry, and the DTx East: Boston, Massachusetts, 2023 summit has experts from a broad range of stakeholders in the digital therapeutics space attending, including leading DTx companies, pharma companies, healthcare payers and providers, governmental institutions, academia, policymakers and more. The conference program includes a wide range of topics from reimbursement, regulation, patient insights, clinical trials, commercialization, adoption, and more. The number of attendees usually counts several hundred.
In his keynote presentation, Kim Baden-Kristensen will provide answers to fundamental questions about where DTx sit within Digital Health, what is key to defining the DTx industry, how to identify the right target audiences and the intended use, provide clinical evidence and what go-to-market strategies can best possibly scale the potential of DTx for the benefit of patients and healthcare systems. In this context, Kim will showcase Brain+’ portfolio of digital dementia products and share how the company is building clinical evidence for its digital delivery of Cognitive Stimulation Therapy (CST). CST is the world leading non-pharmacological treatment of dementia, which today is offered as an analogue therapist-led and activity-based group therapy. Brain+ is pioneering the digitalization of CST with global experts, including the inventor of CST, and started the commercial introduction of a first version of its most mature CST-based product, CST-Therapist Companion, in late 2022. Upgraded versions of the product including scalable and customizable content is expected ready for commercialization in Denmark, Germany and the UK in 2024.
For further information about Brain+, please contact:
Kim Baden-Kristensen, MSc.
CEO and Co-founder:
Phone: + 45 31393317 (text message)
Mail: [email protected]
About Brain+ A/S
Brain+ A/S (Nasdaq Copenhagen: BRAINP) develops and commercializes digital therapeutics for dementia and Alzheimer’s disease. Bringing effective digitally-delivered dementia therapies to those in need, serving a million people with dementia, care-givers and clinicians by 2030. For more information, please visit the company's web page: www.brain-plus.com
